132 related articles for article (PubMed ID: 25627305)
1. [Legionella pneumonia after infliximab in a patient with rheumatoid arthritis].
Giassi Kde S; Furlanetto V; Fialho S; Gomes Ribeiro G; Pereira IA
Rev Bras Reumatol; 2014; 54(5):397-9. PubMed ID: 25627305
[TBL] [Abstract][Full Text] [Related]
2. A severe complication of anti-TNF alfa treatment.
Fabroni C; Gori A; Prignano F; Lotti T
G Ital Dermatol Venereol; 2010 Dec; 145(6):775-7. PubMed ID: 21139554
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists.
Tubach F; Ravaud P; Salmon-Céron D; Petitpain N; Brocq O; Grados F; Guillaume JC; Leport J; Roudaut A; Solau-Gervais E; Lemann M; Mariette X; Lortholary O;
Clin Infect Dis; 2006 Nov; 43(10):e95-100. PubMed ID: 17051484
[TBL] [Abstract][Full Text] [Related]
4. First reported United States case of Legionella pneumophila serogroup 1 pneumonia in a patient receiving anti-tumor necrosis factor-alpha therapy.
Jinno S; Pulido S; Pien BC
Hawaii Med J; 2009 Jun; 68(5):109-12. PubMed ID: 19583105
[TBL] [Abstract][Full Text] [Related]
5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
6. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
7. A case of legionellosis during treatment with a TNFalpha antagonist.
Wondergem MJ; Voskuyl AE; van Agtmael MA
Scand J Infect Dis; 2004; 36(4):310-1. PubMed ID: 15198192
[TBL] [Abstract][Full Text] [Related]
8. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
9. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
10. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.
Mori S; Imamura F; Kiyofuji C; Sugimoto M
Mod Rheumatol; 2006; 16(4):251-5. PubMed ID: 16906378
[TBL] [Abstract][Full Text] [Related]
11. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
12. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
Murdaca G; Spanò F; Puppo F
Expert Opin Drug Saf; 2013 Nov; 12(6):801-4. PubMed ID: 23889669
[TBL] [Abstract][Full Text] [Related]
13. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
Koike R; Takeuchi T; Eguchi K; Miyasaka N;
Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
[TBL] [Abstract][Full Text] [Related]
14.
Borrás-Blasco J; Cortes X; Fernandez-Martinez S; Casterá E; Antequera B
Am J Health Syst Pharm; 2017 Feb; 74(4):209-212. PubMed ID: 28179246
[TBL] [Abstract][Full Text] [Related]
15. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
16. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
[TBL] [Abstract][Full Text] [Related]
17. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
18. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
[TBL] [Abstract][Full Text] [Related]
19. Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis.
Phillips C; Zeringue AL; McDonald JR; Eisen SA; Ranganathan P
PLoS One; 2015; 10(11):e0143286. PubMed ID: 26599370
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.
Vasconcellos JB; Pereira DD; Vargas TJ; Levy RA; Pinheiro GD; Cursi ÍB
An Bras Dermatol; 2016; 91(5 suppl 1):137-139. PubMed ID: 28300922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
